Seattle HIV vaccines, antibody prevention, and treatment initiative
Seattle Clinical Trials Unit
['FUNDING_OTHER'] · FRED HUTCHINSON CANCER CENTER · NIH-11228773
This project tests HIV vaccines, antibody-based prevention, and improved treatments for adults living with or at risk for HIV.
Quick facts
| Phase | ['FUNDING_OTHER'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | FRED HUTCHINSON CANCER CENTER (nih funded) |
| Locations | 1 site (SEATTLE, UNITED STATES) |
| Trial ID | NIH-11228773 on ClinicalTrials.gov |
What this research studies
You would be joining clinical research led by the Seattle-Lausanne Clinical Trials Unit that runs trials through the HVTN and ACTG networks. The work includes testing HIV vaccine candidates, combination broadly neutralizing antibody immunoprophylaxis to prevent infection, and improved therapies aimed at better health and possible sustained viral remission. Some studies also aim to improve vaccine protection against Mycobacterium tuberculosis in people with HIV. Participation usually involves clinic visits for vaccinations or infusions, blood tests, and follow-up over months to years.
Who could benefit from this research
Good fit: Ideal candidates are adults (typically age 21+) who are either living with HIV or at risk for HIV and willing to attend clinic visits and study procedures.
Not a fit: Children, people who cannot travel to the clinic locations, or those who do not meet specific medical or safety criteria for a given trial are unlikely to participate or benefit directly.
Why it matters
Potential benefit: If successful, this work could lead to vaccines or antibody regimens that prevent HIV and better therapies that reduce illness and may allow long-term remission without daily drugs.
How similar studies have performed: Related HVTN and ACTG trials have produced promising vaccine candidates and early positive results with broadly neutralizing antibodies, but a widely effective HIV vaccine and a reliable remission strategy remain unproven.
Where this research is happening
SEATTLE, UNITED STATES
- FRED HUTCHINSON CANCER CENTER — SEATTLE, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: MCELRATH, MARGARET JULIANA — FRED HUTCHINSON CANCER CENTER
- Study coordinator: MCELRATH, MARGARET JULIANA
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Acquired Immune Deficiency Syndrome, Acquired Immune Deficiency Syndrome Virus, Acquired Immunodeficiency Syndrome, Acquired Immunodeficiency Syndrome Virus